Canaccord analyst Mark Massaro introduced his top picks for 2019 in the Diagnostics and Tools space as he expects new tests will generate clinical and economic utility to patients and payors, which will pace positive returns in 2019. His top picks include Illumina (ILMN) with a $375 price target, Exact Sciences (EXAS) with an $87 price target, Heska (HSKA) with a $123 target, Natera (NTRA) with a $25 target, OraSure (OSUR) with an $18 target and Quidel (QDEL) with a $70 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.